OncoMatch/Clinical Trials/NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Is NCT05990465 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pirtobrutinib and LV20.19 CAR T cells for non hodgkin lymphoma.
Treatment: Pirtobrutinib · LV20.19 CAR T cells — This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Demographics
Prior therapy
Must have received: anti-CD20 antibody (rituximab) — with chemotherapy regimen appropriate for disease
Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody with combination anthracycline based chemotherapy regimen
Cannot have received: anti-CD20 antibody
Anti-CD20 antibody treatment within 4 weeks of cell infusion
Cannot have received: anti-CD19 antibody
Anti-CD19 antibody treatment within 4 weeks of cell infusion
Cannot have received: cytotoxic chemotherapy
Cytotoxic chemotherapy treatment within 14 days ... prior to apheresis collection for CAR-T cells
Lab requirements
Blood counts
ANC ≥1000/μL (no G-CSF within 7 days or pegylated G-CSF within 14 days unless bone marrow involvement); Platelets ≥50,000/μL (no transfusion within 7 days unless bone marrow involvement); Hemoglobin ≥8g/dL (transfusions allowed)
Kidney function
creatinine clearance ≥50 ml/min (apheresis/CAR-T/pirtobrutinib start); ≥40 ml/min (pirtobrutinib maintenance)
Liver function
AST and ALT <3 x ULN; serum bilirubin and alkaline phosphatase <3 x ULN, or considered not clinically significant as per the clinical PI's discretion (e.g., Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
Cardiac function
NYHA I or II AND LVEF ≥45% (by ECHO or MUGA); room air oxygen saturation ≥92%
See organ function criteria for pirtobrutinib bridging, maintenance, and apheresis/CAR-T cells.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05990465 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD20 antibody, anti-CD19 antibody, cytotoxic chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 81 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify